Seeking Alpha

Endo Health Solutions (ENDP) issues a statement in response to the FDA's decision to deny its...

Endo Health Solutions (ENDP) issues a statement in response to the FDA's decision to deny its citizen petition and approve a generic version of Lidoderm, saying it's disappointed with the outcome. The company says approval of a generic version without requiring clinical endpoint studies is inadequate to establish the safety and efficacy of the medication.
Comments (3)
  • TruffelPig
    , contributor
    Comments (4097) | Send Message
     
    I did read this twice - shouldn't it say adequate in the last sentence? Somehow I do not get this one.
    23 Aug 2012, 07:54 PM Reply Like
  • Paul Price
    , contributor
    Comments (1514) | Send Message
     
    No, ENDP is trying to stop the release of generic competition to THEIR brand name drug.
    23 Aug 2012, 08:44 PM Reply Like
  • TruffelPig
    , contributor
    Comments (4097) | Send Message
     
    Ah, ok. TY.
    23 Aug 2012, 09:36 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs